Elevation announces positive Phase IIb COPD data
This article was originally published in Scrip
Executive Summary
In a Phase IIb study of its nebulized long-acting muscarinic antagonist EP-101, Elevation Pharmaceuticals said the drug showed a clinically meaningful and statistically significant improvement in lung function versus placebo for patients with moderate to severe chronic obstructive pulmonary disease (COPD) as well as bronchodilation comparable to two established therapies.